Astrazeneca Plc · LSE:AZN
Astrazeneca — JP Morgan Healthcare Conference 2026
25 slides from Astrazeneca's conference presentation, Jan 13, 2026
Slide 1: JP Morgan Healthcare Conference
JP Morgan Healthcare Conference Aradhana Sarin, EVP & CFO 13 January 2026
Slide 2: Cautionary statements regarding forward-looking statements
Cautionary statements regarding forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certai
Slide 3: Continued strong commercial performance in 9M 2025 and unprecedented pipeline delivery
Continued strong commercial performance in 9M 2025 and unprecedented pipeline delivery 9M 2025: 5 focus therapeutic areas: Sustained commercial momentum Oncology BioPharmaceuticals Rare Disease +11% Total Revenue1 +15% Core EPS1 Cardiovascular, Respiratory & Vaccines & Renal & Immunology Immune Meta
Slide 4: 9M 2025 – growth driven by global reach and diverse sources of business
9M 2025 – growth driven by global reach and diverse sources of business +16% 9M 2025 | % Total Revenue by therapy area +8% V&I: 826 +2% R&I: +13% Oncology CVRM R&I V&I Other Rare Disease Strength across 6,493 +6% 43% 23% 15% 2% 2% 16% therapy areas 9M 2025 | Total Revenue ($m)1 +5% CVRM: 18,591 9,80
Slide 5: Ambition – $80bn Total Revenue by 2030 & sustained 2030+ growth
Ambition – $80bn Total Revenue by 2030 & sustained 2030+ growth Beyond 2030 Working on “today, tomorrow and the day after" ADCs and Radioconjugates Illustrative only, not to scale Cell therapy and T-cell engagers Launching key NMEs $80bn Gene therapy AZD0120 saruparib camizestrant volrustomig Next-g
Slide 6: Continued momentum delivering across diverse pipeline
Continued momentum delivering across diverse pipeline Key Phase III trial readouts in 2025 drive growth to 2030 and beyond Oncology BioPharmaceuticals Rare Disease NME NME SERENA-6 POTOMAC KALOS/LOGOS CARES camizestrant Imfinzi Breztri anselamimab NME NME MATTERHORN DESTINY-Breast11 PREVAIL Imfinzi
Slide 7: Disciplined R&D investment and portfolio prioritisation drives our industry-leading pipeline
Disciplined R&D investment and portfolio prioritisation drives our industry-leading pipeline Comprehensive strategic planning, Therapeutic area strategy assessing broad opportunities for World-class team leadership across therapy areas Mid/long term Optimise enterprise aspirations across Robust orga
Slide 8: Expanding deep pipeline with increasing value
Expanding deep pipeline with increasing value Diverse mix of modalities and therapy areas Growing number of late-stage Increasing investment into our Number of patients in active trials assets1 with increasing pipeline transformative technologies to significantly increasing3, supporting value per in
Slide 9: Leveraging AI across the value chain to drive outcomes, efficiency, productivity and innovation
Leveraging AI across the value chain to drive outcomes, efficiency, productivity and innovation Development Sales and marketing Discovery Manufacturing, Healthcare delivery supply chain & CMC Select case studies: AI Development Agent (AIDA) | Agentic system for Quantitative continuous scoring (QCS)
Slide 10: Substantial progress with transformative technologies to underpin our next wave of growth beyond 2030
Substantial progress with transformative technologies to underpin our next wave of growth beyond 2030 Weight management and Cell therapy and ADCs and Radioconjugates Next-gen IO bispecifics CV risk factors T-cell engagers Establish and lead in new Replace systemic Develop scalable cell weight manage
Slide 11: Ambition to transform care across cardiometabolic diseases
Ambition to transform care across cardiometabolic diseases laroprovstat | Differentiated oral PCSK9i with Weight management portfolio | Multiple pivotal Phase III data expected in 2027 mechanisms to readout Phase II data in 2026 Ongoing Phase II programme: Small molecule, LDL-C reduction Once for la
Slide 12: baxdrostat: First and best-in-class potential in hard-to-control hypertension
baxdrostat: First and best-in-class potential in hard-to- control hypertension Significant baxdrostat | Differentiated clinical profile Strong commercial unmet need Bax24 results showed 14mmHg placebo-adjusted reduction in footprint 24-hour AMBP to week 123 1.4bn US cardiologists and majority of pri
Slide 13: Rapidly advancing broad high value portfolio of ADCs
Rapidly advancing broad high value portfolio of ADCs Expanding leadership position in growing ADC market Rapidly progressing assets into Phase III Phase I Phase II Phase III CLARITY-Gastric01 Readout sone-vedo sone-vedo | CLDN18.2 $45bn+ 2L Claudin 18.2 gastric cancer H1’26 puxi-sam | B7-H4 Late-sta
Slide 14: Leading in next-wave IO bispecifics
Leading in next-wave IO bispecifics rilvegostomig | Further confidence driven by Broad and diverse programme for ARTEMIDE-01 Phase I/II data at ESMO 20251 rilvegostomig and volrustomig Stage IV NSCLC PD-L1 TPS ≥50%, CPI-naïve (n=34) 100 2030 global market $60bn+ Change in target lesions from baselin
Slide 15: Differentiated efficacy emerging with cell therapy and immune engagers
Differentiated efficacy emerging with cell therapy and immune engagers AZD0120 | Potential best-in-class cell therapy for surovatamig | Transformative potential across multiple myeloma haematologic malignancies Dual CD19/BCMA CAR-T CD19/CD3 bispecific T-cell engager DURGA-1 Phase Ib data for multipl
Slide 16: Capital allocation priorities remain unchanged
Capital allocation priorities remain unchanged Increasing Net cash inflow from operating activities +37% in 9M 2025 Reinvestment Strong in our investment- 1.2x business grade credit Net Debt/ (incl. CapEx) rating Adjusted EBITDA1 CapEx investment to support revenue growth Value- +$0.20 Progressive e
Slide 17: Catalyst rich period continues, remain on track for 2030 ambition
Catalyst rich period continues, remain on track for 2030 ambition Key high-value Phase III readouts: H1 2026 H2 2026 AVANZAR CLARITY-Gastric01 TROPION-Lung15 DAISY Datroway + Imfinzi sonesitatug vedotin Datroway ± Tagrisso Saphnelo 1L NSQ/NSQ TROP2+ NSCLC 2L+ CLDN18.2+ gastric cancer 2L EGFRm NSCLC
Slide 18: Appendix
Appendix
Slide 19: Strengthening operations in US to power future growth
AP P E ND I X | US operations Strengthening operations in US to power future growth Investments support $80bn Total Revenue ambition by 2030 – Provides greater clarity around pricing and 3-year exemption Expanding manufacturing Voluntary from tariffs footprint in US agreement with – MFN pricing for
Slide 20: Our evolved Sustainability strategy at AstraZeneca
AP P E ND I X | Sustainability Our evolved Sustainability strategy at AstraZeneca How we make a sustainable impact: through the power of science and innovation, we are taking action on climate and nature, health equity and health systems resilience How we do business: we are guided by our values and
Slide 21: AstraZeneca in non-small cell lung cancer
AP P E ND I X | Oncology tumour maps AstraZeneca in non-small cell lung cancer Resectable Unresectable Metastatic Stg. I Stg. II-III Stg. I-II Stg. III 1L 2L 3L+ Est. epi (G7, 2025) ~150K ~70K ~50K ~100K ~310K ~190K ~70K Imfinzi CRT → Imfinzi Imfinzi + Imjudo + CTx POSEIDON AEGEAN PACIFIC Datroway +
Slide 22: AstraZeneca in breast cancer
AP P E ND I X | Oncology tumour maps AstraZeneca in breast cancer Early Metastatic Neoadjuvant Adjuvant 1st line 2nd line 3rd line 4th line + Est. epi (G7, 2025) 540k 135k 100k 75k 60k HER2-positive Enhertu → THP NST→ residual disease → Enhertu Enhertu ± pertuzumab Enhertu Enhertu 15-20% DESTINY-Bre
Slide 23: AstraZeneca in gastric cancer
AP P E ND I X | Oncology tumour maps AstraZeneca in gastric cancer Early Advanced/Metastatic Stage II/III 1st line 2nd line 3rd line Est. epi (G7, 2025) 50k 90k 60k 30k Enhertu + rilvegostomig + FP HER2-positive ARTEMIDE-Gastric01 Enhertu Enhertu 20% DESTINY-Gastric02, 04 DESTINY-Gastric01 Enhertu +
Slide 24: Glossary
AP P E ND I X | Glossary Glossary 1L, 2L, 3L, 4L first-, second-, third-line epi epidemiology NSQ non-squamous 9M nine months EPS earnings per share NST neoadjuvant systemic treatment ADC antibody-drug conjugate ERoW Established Rest of World NYSE New York Stock Exchange adv. advanced ESMO European
Slide 25: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis